Tai Mei Ti A P P·2026-01-29 06:30Group 1 - The Nipah virus outbreak in West Bengal, India, has reported 5 confirmed cases, with a high fatality rate of 40%-75% and no approved vaccines or treatments available globally [2][10] - The outbreak has triggered a short-lived surge in the In Vitro Diagnostics (IVD) sector in the A-share market, with significant stock price increases for companies like Cap Bio and Zhijiang Bio on January 26, followed by a rapid decline [4][12] - The IVD industry's response to the outbreak reflects a short-term reaction pattern to public health events, indicating a need to shift focus from sporadic events to long-term value driven by policy support, growing health service demand, and technological upgrades [6][15] Group 2 - The high mortality rate of the Nipah virus and the absence of specific vaccines and effective therapies have become emotional anchors for market reactions [7] - The IVD sector's core companies have seen significant price adjustments, with many stocks down over 70% from their historical highs during the COVID-19 pandemic, leading to a perception of "low valuation + oversold" conditions [7][13] - The actual demand for testing related to the Nipah virus is insufficient to sustain prolonged stock price increases, as the virus has a low transmission efficiency and primarily causes localized outbreaks [13][19] Group 3 - The IVD industry is currently experiencing a transformation phase, moving away from reliance on sporadic pandemics to a focus on regular diagnostic needs driven by an aging population and increased health awareness [19][20] - The market for medical testing in China is projected to grow from 17.97 billion yuan in 2018 to 71.92 billion yuan by 2027, with a compound annual growth rate of 19.1% [19] - Policy support, such as the "14th Five-Year Plan for National Health," aims to enhance the medical testing industry, providing a framework for technological innovation and industry upgrades [19][20]